Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

CRISPR Therapeutics (CRSP) Financials

CRISPR Therapeutics logo
$50.36 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$50.15 -0.21 (-0.41%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CRISPR Therapeutics

Annual Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -26 -23 -68 -165 67 -349 373 -650 -154 -366 -579
Consolidated Net Income / (Loss)		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Net Income / (Loss) Continuing Operations		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Total Pre-Tax Income 		-26 -23 -67 -164 67 -348 380 -651 -151 -363 -578
Total Operating Income		 -26 -68 -65 -159 47 -354 374 -673 -223 -467 -665
Total Gross Profit		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37 3.51
Total Revenue		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37 3.51
Operating Revenue		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37 3.51
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 26 73 106 162 243 355 541 674 594 504 668
Selling, General & Admin Expense		 13 31 36 48 63 86 100 102 76 73 74
Research & Development Expense		 13 42 70 114 179 221 341 462 387 310 381
Other Operating Expenses / (Income)		 - - - - - 48 101 110 130 121 213
Total Other Income / (Expense), net		 -0.09 45 -1.96 -5.49 21 6.38 6.00 23 72 104 87
Other Income / (Expense), net		 0.02 79 -0.20 -1.21 26 6.38 6.00 23 72 104 87
Income Tax Expense		 0.01 0.48 1.75 0.55 0.45 0.81 1.87 -0.33 2.89 3.59 3.63
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.01 0.02 -0.04 0.02 -0.02 -0.04 4.98 0.08 -0.07 0.07 -2.98
Basic Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.23 ($5.29) $4.97 ($8.36) ($1.94) ($4.34) ($6.47)
Weighted Average Basic Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 54.39M 65.95M 75.95M 77.75M 79.22M 84.36M 89.93M
Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.17 ($5.29) $4.70 ($8.36) ($1.94) ($4.34) ($6.47)
Weighted Average Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 56.93M 65.95M 80.39M 77.75M 79.22M 84.36M 89.93M
Weighted Average Basic & Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 60.85M 75.43M 77.07M 78.65M 80.28M 85.77M 95.99M

Quarterly Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -112 89 -117 -126 -86 -34 -134 -209 -106 -128 -123
Consolidated Net Income / (Loss)		 -112 89 -117 -126 -86 -37 -136 -209 -106 -131 -123
Net Income / (Loss) Continuing Operations		 -112 89 -117 -126 -86 -37 -136 -209 -106 -131 -123
Total Pre-Tax Income 		-112 90 -116 -125 -85 -37 -135 -207 -106 -130 -122
Total Operating Income		 -132 70 -141 -151 -110 -65 -148 -229 -132 -155 -130
Total Gross Profit		 0.00 201 0.50 0.52 0.60 36 0.87 0.89 0.89 0.86 1.46
Total Revenue		 0.00 201 0.50 0.52 0.60 36 0.87 0.89 0.89 0.86 1.46
Operating Revenue		 0.00 201 0.50 0.52 0.60 36 0.87 0.89 0.89 0.86 1.46
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 132 132 141 152 111 100 149 230 133 156 132
Selling, General & Admin Expense		 18 16 18 19 17 18 19 19 17 18 17
Research & Development Expense		 91 95 76 80 82 82 72 166 59 84 69
Other Operating Expenses / (Income)		 23 20 47 52 11 - 58 45 57 54 46
Total Other Income / (Expense), net		 21 20 25 26 25 28 14 22 26 25 8.16
Other Income / (Expense), net		 21 20 25 26 25 28 14 22 26 25 8.16
Income Tax Expense		 0.41 0.23 0.72 1.29 0.88 0.70 1.11 1.29 0.62 0.61 0.84
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.05 -0.06 0.01 -0.00 -0.08 -3.31 -2.30 0.09 0.03 -3.06 0.03
Basic Earnings per Share		 ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28)
Weighted Average Basic Shares Outstanding		 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M
Diluted Earnings per Share		 ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28)
Weighted Average Diluted Shares Outstanding		 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M
Weighted Average Basic & Diluted Shares Outstanding		 79.43M 80.28M 84.92M 85.17M 85.35M 85.77M 86.36M 90.95M 95.30M 95.99M 96.45M

Annual Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 155 162 -76 217 489 237 -246 -716 177 -91 49
Net Cash From Operating Activities		 59 -53 -70 -96 57 -238 539 -496 -260 -143 -345
Net Cash From Continuing Operating Activities		 59 -53 -70 -96 57 -238 539 -496 -263 -143 -345
Net Income / (Loss) Continuing Operations		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Consolidated Net Income / (Loss)		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Depreciation Expense		 0.13 0.93 3.02 3.52 4.73 9.18 18 24 20 19 19
Non-Cash Adjustments To Reconcile Net Income		 3.11 -35 21 55 34 68 116 110 64 48 145
Changes in Operating Assets and Liabilities, net		 82 4.23 -25 11 -48 33 27 20 -194 156 72
Net Cash From Investing Activities		 -1.15 32 -8.31 -2.77 1.33 -541 -1,035 -259 375 -280 -32
Net Cash From Continuing Investing Activities		 -1.15 32 -8.31 -2.77 1.33 -541 -1,035 -259 375 -280 -32
Purchase of Property, Plant & Equipment		 -1.15 -3.02 -7.81 -2.77 -6.68 -18 -82 -37 -9.47 -1.90 -0.91
Acquisitions		 - -0.10 - - 8.01 - 0.00 0.00 -2.50 0.00 -25
Purchase of Investments		 - - -0.50 0.00 0.00 -594 -1,509 -1,418 -1,066 -1,486 -1,018
Sale and/or Maturity of Investments		 - - - 0.00 0.00 71 556 1,196 1,453 1,208 1,012
Net Cash From Financing Activities		 97 183 2.61 316 431 1,016 251 39 63 332 426
Net Cash From Continuing Financing Activities		 97 183 2.61 316 431 1,016 251 39 63 332 426
Issuance of Common Equity		 - 89 - 316 431 1,016 251 39 63 332 426
Effect of Exchange Rate Changes		 0.01 - - - 0.02 0.04 -0.01 -0.08 0.07 -0.02 0.10

Quarterly Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 83 -139 318 -223 -259 73 -63 -42 93 61 72
Net Cash From Operating Activities		 -40 -96 110 -96 -107 -50 -54 -114 -85 -93 -109
Net Cash From Continuing Operating Activities		 -40 -96 110 -96 -107 -50 -54 -114 -85 -93 -109
Net Income / (Loss) Continuing Operations		 -112 89 -117 -126 -86 -37 -136 -209 -106 -131 -123
Consolidated Net Income / (Loss)		 -112 89 -117 -126 -86 -37 -136 -209 -106 -131 -123
Depreciation Expense		 4.93 4.90 4.83 4.85 4.74 4.84 4.74 4.65 4.43 5.66 4.32
Non-Cash Adjustments To Reconcile Net Income		 15 14 11 15 15 6.79 22 107 6.47 9.76 25
Changes in Operating Assets and Liabilities, net		 53 -204 210 10 -40 -24 55 -17 11 23 -15
Net Cash From Investing Activities		 121 -81 -98 -127 -162 106 -20 70 -119 37 -411
Net Cash From Continuing Investing Activities		 121 -81 -98 -127 -162 106 -20 70 -119 37 -411
Purchase of Property, Plant & Equipment		 -2.12 -0.74 -0.72 -0.71 -0.22 -0.25 -0.21 -0.12 -0.07 -0.52 -0.50
Purchase of Investments		 -245 -368 -334 -476 -409 -267 -206 -215 -334 -263 -751
Sale and/or Maturity of Investments		 370 287 237 350 248 373 186 310 215 301 340
Net Cash From Financing Activities		 1.56 39 306 -0.47 9.64 17 11 2.26 297 116 592
Net Cash From Continuing Financing Activities		 1.56 39 306 -0.47 9.64 17 11 2.26 297 116 592
Repayment of Debt		 - - - - - - 0.00 - - - -14
Issuance of Debt		 - - - - - - 0.00 - - - 600
Issuance of Common Equity		 1.56 39 306 -0.47 9.64 17 11 2.26 297 116 5.44
Effect of Exchange Rate Changes		 -0.05 0.06 -0.01 0.00 0.08 -0.09 0.04 0.08 -0.03 0.00 -0.03

Annual Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 159 345 271 489 1,067 1,828 2,752 2,243 2,230 2,242 2,265
Total Current Assets		 157 320 248 466 988 1,717 2,418 1,853 1,908 1,937 1,986
Cash & Equivalents		 156 316 240 457 944 1,169 923 212 389 298 348
Short-Term Investments		 - - - - 0.00 522 1,456 1,603 1,304 1,606 1,628
Accounts Receivable		 0.34 3.16 2.63 0.09 0.10 0.14 0.31 0.00 200 25 0.00
Prepaid Expenses		 0.54 1.51 6.00 9.66 44 26 38 38 14 8.31 9.84
Plant, Property, & Equipment, net		 1.33 21 19 19 31 42 138 164 152 134 116
Total Noncurrent Assets		 1.26 3.75 4.10 4.12 48 69 197 226 170 171 164
Other Noncurrent Operating Assets		 0.10 0.20 0.61 3.83 48 69 197 173 168 171 164
Total Liabilities & Shareholders' Equity		 159 345 271 489 1,067 1,828 2,752 2,243 2,230 2,242 2,265
Total Liabilities		 124 112 84 97 127 164 352 368 347 310 343
Total Current Liabilities		 10 22 15 28 57 94 120 121 109 88 149
Accounts Payable		 1.58 4.57 1.64 5.07 5.94 9.09 15 27 38 15 11
Accrued Expenses		 8.43 16 11 21 30 54 91 78 45 41 89
Current Deferred Revenue		 0.00 1.03 1.03 1.30 0.96 2.34 1.01 0.00 4.11 3.85 16
Current Deferred & Payable Income Tax Liabilities		 0.08 0.02 0.35 0.40 0.58 10 0.72 0.14 0.44 0.45 1.11
Other Current Liabilities		 0.06 0.06 0.14 0.12 19 19 12 16 21 28 32
Total Noncurrent Liabilities		 114 90 69 69 70 69 233 246 238 222 194
Long-Term Debt		 38 - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 0.28 0.19 0.31 0.24 58 58 220 234 224 210 194
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Total Preferred & Common Equity		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Total Common Equity		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Common Stock		 4.82 290 313 684 1,164 2,238 2,601 2,737 2,881 3,296 3,865
Retained Earnings		 -34 -57 -125 -292 -225 -574 -196 -846 -1,000 -1,366 -1,948
Treasury Stock		 0.00 0.00 0.00 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.03 0.01 -0.01 0.01 -0.08 -5.07 -16 1.91 1.84 4.82

Quarterly Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 2,353 2,244 2,197 2,087 2,439 2,340 2,256 2,166 2,030 2,245 2,726
Total Current Assets		 1,933 1,908 1,860 1,761 2,120 2,010 1,944 1,868 1,734 1,929 2,448
Cash & Equivalents		 494 344 445 528 707 484 226 235 194 286 423
Short-Term Investments		 1,402 1,539 1,323 1,212 1,401 1,517 1,710 1,620 1,528 1,629 2,018
Accounts Receivable		 0.05 0.00 70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Prepaid Expenses		 37 25 21 21 11 8.79 8.25 12 12 13 6.58
Plant, Property, & Equipment, net		 166 162 159 156 147 143 139 129 125 121 112
Total Noncurrent Assets		 255 174 178 170 172 186 174 169 171 195 165
Other Noncurrent Operating Assets		 177 168 173 170 172 175 174 169 171 167 165
Total Liabilities & Shareholders' Equity		 2,353 2,244 2,197 2,087 2,439 2,340 2,256 2,166 2,030 2,245 2,726
Total Liabilities		 399 389 381 359 355 359 316 337 319 329 911
Total Current Liabilities		 151 147 133 111 119 128 90 119 104 119 136
Accounts Payable		 32 45 28 26 16 9.45 16 13 9.75 12 14
Accrued Expenses		 103 86 90 66 76 92 47 85 74 84 75
Current Deferred Revenue		 0.00 0.00 0.00 3.50 4.07 4.76 4.48 3.02 2.13 1.30 15
Current Deferred & Payable Income Tax Liabilities		 4.27 0.27 0.56 0.18 1.21 0.45 0.84 1.24 0.72 3.43 0.64
Other Current Liabilities		 12 16 15 15 21 21 22 18 18 18 32
Total Noncurrent Liabilities		 249 243 248 248 236 231 227 217 214 210 775
Long-Term Debt		 - - - - - - - - - - 585
Other Noncurrent Operating Liabilities		 236 230 236 232 223 218 214 205 202 198 190
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,954 1,855 1,816 1,728 2,084 1,981 1,940 1,829 1,711 1,916 1,815
Total Preferred & Common Equity		 1,954 1,855 1,816 1,728 2,084 1,981 1,940 1,829 1,711 1,916 1,815
Total Common Equity		 1,954 1,855 1,816 1,728 2,084 1,981 1,940 1,829 1,711 1,916 1,815
Common Stock		 2,712 2,764 2,802 2,824 3,202 3,227 3,258 3,327 3,418 3,728 3,887
Retained Earnings		 -736 -899 -977 -1,089 -1,116 -1,243 -1,329 -1,502 -1,710 -1,817 -2,070
Treasury Stock		 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 -22 -9.39 -8.91 -6.80 -1.55 -2.88 11 4.14 4.04 4.99 -1.94

Annual Metrics And Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 1,990.69% 693.90% -92.38% 9,169.85% -99.75% 127,154.94% -99.87% 30,885.48% -89.95% -90.59%
EBITDA Growth		 -274.89% 144.19% -646.75% -153.37% 149.48% -537.27% 217.30% -257.57% 79.10% -162.37% -62.63%
EBIT Growth		 -274.66% 140.38% -724.59% -146.98% 145.44% -578.28% 209.04% -271.40% 76.83% -140.62% -59.37%
NOPAT Growth		 -288.25% -164.80% 5.11% -145.86% 141.73% -634.38% 249.81% -226.78% 66.94% -109.66% -42.44%
Net Income Growth		 -87.04% 10.17% -194.62% -141.35% 140.52% -621.80% 208.25% -272.16% 76.37% -138.43% -58.80%
EPS Growth		 -356.85% 62.65% 9.52% -101.17% 134.01% -552.14% 188.85% -277.87% 76.79% -123.71% -49.08%
Operating Cash Flow Growth		 1,339.89% -188.95% -32.60% -37.30% 158.89% -520.57% 326.11% -191.98% 47.48% 45.17% -141.65%
Free Cash Flow Firm Growth		 0.00% -169.00% -69.66% -34.06% 86.57% -1,554.72% 243.70% -240.78% 26.65% 50.07% -128.33%
Invested Capital Growth		 0.00% -3.49% 35.82% -17.02% 93.26% -500.53% 177.90% -65.42% 2,561.61% -84.90% -291.18%
Revenue Q/Q Growth		 0.00% 0.00% 272.16% -91.16% 36.16% -99.07% 1.39% -91.50% 118.35% -81.60% -90.84%
EBITDA Q/Q Growth		 0.00% 0.00% -525.40% -43.15% 60,445.31% -67.53% -7.58% 3.55% 61.46% -58.14% -19.87%
EBIT Q/Q Growth		 0.00% 0.00% -418.14% -41.98% 1,870.63% -65.49% -8.73% 3.48% 58.17% -53.36% -19.27%
NOPAT Q/Q Growth		 0.00% 0.00% 28.90% -40.98% 800.32% -50.38% -8.80% 2.06% 47.47% -40.37% -15.70%
Net Income Q/Q Growth		 0.00% 0.00% -32.99% -40.71% 693.03% -65.12% -8.31% 4.51% 56.55% -52.86% -19.11%
EPS Q/Q Growth		 0.00% 0.00% -144.53% -37.60% 348.94% -72.88% -0.84% 1.88% 56.50% -54.45% -16.37%
Operating Cash Flow Q/Q Growth		 0.00% -259.65% 2.94% -16.36% 127.35% -55.01% -0.89% -5.83% 6.22% 24.38% -14.06%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -22.04% 67.38% -25.66% -6.88% -7.39% -10.60% 32.57% -3.52%
Invested Capital Q/Q Growth		 0.00% 0.00% 29.13% 11.88% 88.51% -15.03% -42.83% 136.68% 1,655.34% 604.06% -91.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -10,358.70% 218.96% -150.79% -5,013.89% 26.76% -47,131.02% 43.44% -52,281.14% -35.26% -920.31% -15,911.28%
Operating Margin		 -10,416.60% -1,319.33% -157.69% -5,087.80% 16.14% -49,295.55% 40.82% -56,190.40% -59.95% -1,250.38% -18,933.65%
EBIT Margin		 -10,410.12% 201.05% -158.17% -5,126.54% 25.13% -48,408.34% 41.48% -54,298.83% -40.60% -971.93% -16,466.24%
Profit (Net Income) Margin		 -10,456.68% -449.30% -166.74% -5,281.08% 23.09% -48,520.86% 41.28% -54,271.70% -41.38% -981.54% -16,569.77%
Tax Burden Percent		 100.03% 102.13% 102.63% 100.34% 99.33% 100.23% 99.51% 99.95% 101.92% 100.99% 100.63%
Interest Burden Percent		 100.42% -218.82% 102.72% 102.67% 92.49% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.67% 0.00% 0.49% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,444.29% -160.45% -303.26% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,435.86% -160.58% -301.05% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,413.87% 152.28% 284.06% 0.00%
Return on Equity (ROE)		 -72.97% -17.30% -32.50% -56.89% 10.04% -26.80% 18.59% -30.42% -8.17% -19.20% -30.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,599.81% -3,347.07% -345.97% -155.73% 0.00%
Operating Return on Assets (OROA)		 -16.13% 4.12% -21.04% -42.13% 9.36% -24.05% 16.57% -26.05% -6.74% -16.22% -25.65%
Return on Assets (ROA)		 -16.20% -9.20% -22.18% -43.40% 8.59% -24.10% 16.49% -26.03% -6.87% -16.38% -25.81%
Return on Common Equity (ROCE)		 59.98% -13.14% -32.50% -56.89% 10.04% -26.80% 18.59% -30.42% -8.17% -19.20% -30.18%
Return on Equity Simple (ROE_SIMPLE)		 88.77% -9.96% -36.39% -42.07% 7.12% -20.96% 15.74% -34.67% -8.16% -18.96% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -48 -45 -111 46 -248 372 -471 -156 -327 -465
NOPAT Margin		 -7,291.62% -923.53% -110.38% -3,561.46% 16.03% -34,506.88% 40.62% -39,333.28% -41.97% -875.26% -13,253.55%
Net Nonoperating Expense Percent (NNEP)		 -13.21% 11.21% -8.23% -15.36% 2.92% -7.65% 0.29% -8.43% 0.12% -2.20% -6.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -25.12% -8.27% -16.90% -24.21%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 5,426.32% 601.39% 87.43% 1,545.90% 21.92% 11,925.87% 10.90% 8,552.92% 20.52% 195.58% 2,095.21%
R&D to Revenue		 5,090.28% 817.93% 170.26% 3,641.90% 61.94% 30,790.26% 37.22% 38,534.64% 104.34% 859.34% 10,856.38%
Operating Expenses to Revenue		 10,516.60% 1,419.33% 257.69% 5,187.80% 83.86% 49,395.55% 59.18% 56,290.40% 159.95% 1,350.38% 19,033.65%
Earnings before Interest and Taxes (EBIT)		 -26 10 -65 -160 73 -348 380 -651 -151 -363 -578
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 11 -62 -157 77 -339 397 -626 -131 -343 -558
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.46 5.13 3.78 3.58 6.50 2.42 1.70 2.64 1.74 2.60
Price to Tangible Book Value (P/TBV)		 0.00 3.47 5.14 3.78 3.58 6.50 2.42 1.70 2.64 1.74 2.60
Price to Revenue (P/Rev)		 0.00 156.18 23.49 474.62 11.61 15,045.33 6.34 2,656.64 13.40 90.03 1,423.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 50.28 0.00 15.56 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 1.99% 0.00% 6.43% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 168.22 186.92 17.51 51.52 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 95.08 17.64 328.44 8.35 12,694.38 3.74 1,097.00 8.83 39.01 860.89
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 43.43 0.00 0.00 31.21 0.00 8.60 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 47.29 0.00 0.00 33.23 0.00 9.01 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 52.09 0.00 9.20 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 42.67 0.00 6.35 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 10.52 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.34 -1.63 -1.33 -1.21 -1.05 -1.01 -1.00 -0.99 -0.95 -0.94 -1.01
Leverage Ratio		 4.50 1.88 1.47 1.31 1.17 1.11 1.13 1.17 1.19 1.17 1.17
Compound Leverage Factor		 4.52 -4.11 1.50 1.35 1.08 1.11 1.13 1.17 1.19 1.17 1.17
Debt to Total Capital		 51.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 51.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 87.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -39.46% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 4.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 6.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 5.24 6.67 8.36 17.09 39.64 11.56 4.64 8.89 6.12 7.66
Noncontrolling Interest Sharing Ratio		 182.20% 24.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.44 14.56 17.12 16.81 17.29 18.21 20.17 15.30 17.54 22.07 13.32
Quick Ratio		 15.39 14.49 16.70 16.46 16.53 17.93 19.85 14.99 17.41 21.97 13.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 65 -45 -76 -102 -14 -226 325 -458 -336 -168 -383
Operating Cash Flow to CapEx		 5,149.74% -1,752.65% -897.02% -3,470.57% 847.95% -1,298.43% 659.66% -1,333.07% -2,749.47% -7,510.47% -37,747.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.13 0.01 0.37 0.00 0.40 0.00 0.17 0.02 0.00
Accounts Receivable Turnover		 0.73 2.95 14.18 2.30 3,097.22 5.92 4,075.56 0.00 0.00 0.33 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.19 0.46 2.06 0.17 11.62 0.02 10.18 0.01 2.35 0.26 0.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 500.95 123.55 25.74 158.55 0.12 61.68 0.09 0.00 0.00 1,100.46 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 500.95 123.55 25.74 158.55 0.12 61.68 0.09 0.00 0.00 1,100.46 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -83 -86 -55 -64 -4.35 -26 20 7.03 187 28 -54
Invested Capital Turnover		 -0.01 -0.06 -0.58 -0.05 -8.42 -0.05 -317.25 0.09 3.82 0.35 -0.27
Increase / (Decrease) in Invested Capital		 -83 -2.90 31 -9.37 60 -22 46 -13 180 -159 -82
Enterprise Value (EV)		 0.00 491 723 1,026 2,418 9,127 3,420 1,314 3,277 1,456 3,022
Market Capitalization		 0.00 807 963 1,483 3,362 10,818 5,799 3,183 4,972 3,360 4,998
Book Value per Share		 ($5.78) $5.85 $4.58 $7.56 $17.02 $23.56 $31.35 $23.95 $23.70 $22.64 $20.17
Tangible Book Value per Share		 ($5.87) $5.84 $4.57 $7.55 $17.01 $23.55 $31.35 $23.95 $23.70 $22.64 $20.17
Total Capital		 74 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Total Debt		 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -118 -316 -240 -457 -944 -1,690 -2,379 -1,868 -1,696 -1,904 -1,976
Capital Expenditures (CapEx)		 1.15 3.02 7.81 2.77 6.68 18 82 37 9.47 1.90 0.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.28 -17 -5.88 -18 -13 -68 -81 -83 106 -54 -139
Debt-free Net Working Capital (DFNWC)		 147 298 234 439 930 1,622 2,298 1,732 1,799 1,849 1,837
Net Working Capital (NWC)		 147 298 234 439 930 1,622 2,298 1,732 1,799 1,849 1,837
Net Nonoperating Expense (NNE)		 7.82 -24 23 54 -20 101 -5.97 179 -2.17 40 116
Net Nonoperating Obligations (NNO)		 -118 -319 -243 -457 -944 -1,690 -2,379 -1,868 -1,696 -1,904 -1,976
Total Depreciation and Amortization (D&A)		 0.13 0.93 3.02 3.52 4.73 9.18 18 24 20 19 19
Debt-free, Cash-free Net Working Capital to Revenue		 -3,755.47% -335.59% -14.35% -576.18% -4.60% -9,453.69% -8.91% -6,961.52% 28.45% -145.99% -3,968.01%
Debt-free Net Working Capital to Revenue		 59,386.64% 5,774.40% 570.47% 14,041.26% 321.30% 225,641.31% 251.12% 144,567.53% 484.71% 4,956.18% 52,323.39%
Net Working Capital to Revenue		 59,386.64% 5,774.40% 570.47% 14,041.26% 321.30% 225,641.31% 251.12% 144,567.53% 484.71% 4,956.18% 52,323.39%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.23 ($5.29) $4.97 ($8.36) ($1.94) ($4.34) ($6.47)
Adjusted Weighted Average Basic Shares Outstanding		 5.04M 39.81M 46.98M 52.28M 54.39M 65.95M 75.95M 77.75M 79.22M 84.36M 89.93M
Adjusted Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.17 ($5.29) $4.70 ($8.36) ($1.94) ($4.34) ($6.47)
Adjusted Weighted Average Diluted Shares Outstanding		 5.04M 39.81M 46.98M 52.28M 56.93M 65.95M 80.39M 77.75M 79.22M 84.36M 89.93M
Adjusted Basic & Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 60.85M 75.43M 77.07M 78.65M 80.28M 85.77M 95.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -48 -45 -111 46 -248 372 -471 -156 -327 -465
Normalized NOPAT Margin		 -7,291.62% -923.53% -110.38% -3,561.46% 16.03% -34,506.88% 40.62% -39,333.28% -41.97% -875.26% -13,253.55%
Pre Tax Income Margin		 -10,453.85% -439.93% -162.47% -5,263.38% 23.24% -48,408.34% 41.48% -54,298.83% -40.60% -971.93% -16,466.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.43% -7.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 95,985,312.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 95,985,312.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.28
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 3,353,333.33% -99.50% -99.26% 0.00% -82.26% 71.63% 72.53% 47.67% -97.58% 68.55%
EBITDA Growth		 37.21% 182.73% -137.79% -67.38% 24.80% -133.63% -17.22% -68.45% -26.22% -291.38% 9.51%
EBIT Growth		 36.19% 174.62% -123.92% -62.88% 23.87% -140.87% -16.42% -65.65% -24.40% -255.08% 9.49%
NOPAT Growth		 27.40% 175.37% -118.01% -58.85% 16.83% -165.15% -5.57% -51.61% -19.91% -139.61% 12.25%
Net Income Growth		 35.75% 180.80% -119.71% -62.60% 23.37% -141.76% -16.64% -64.98% -23.85% -250.07% 9.61%
EPS Growth		 37.05% 180.00% -113.43% -52.04% 28.37% -136.61% -10.49% -61.07% -15.84% -221.95% 18.99%
Operating Cash Flow Growth		 62.12% 15.23% 1,147.32% 28.27% -168.25% 47.92% -149.15% -19.14% 20.84% -84.99% -101.86%
Free Cash Flow Firm Growth		 -36.86% -40.53% -930.14% 66.55% 6.70% 202.68% 6.30% -488.60% 35.27% -122.93% 25.91%
Invested Capital Growth		 37.23% 2,561.61% 30.08% -174.11% 133.35% -84.90% -8.00% 68.29% -801.22% -291.18% -59.84%
Revenue Q/Q Growth		 -100.00% 0.00% -99.75% 2.58% 16.44% 5,828.74% -97.58% 3.12% -0.34% -2.81% 68.75%
EBITDA Q/Q Growth		 -48.65% 188.45% -217.52% -8.32% 33.21% 60.45% -309.68% -55.67% 49.96% -22.63% 5.28%
EBIT Q/Q Growth		 -45.46% 180.17% -229.34% -7.99% 32.01% 56.96% -268.43% -53.65% 48.94% -22.85% 6.08%
NOPAT Q/Q Growth		 -39.05% 174.88% -241.80% -7.59% 27.19% 41.35% -129.80% -54.51% 42.41% -17.19% 15.84%
Net Income Q/Q Growth		 -44.27% 179.67% -230.49% -8.42% 32.01% 56.59% -264.49% -53.35% 48.96% -22.71% 5.88%
EPS Q/Q Growth		 -43.88% 179.43% -227.68% -4.20% 32.21% 59.41% -285.37% -51.90% 51.25% -12.82% 3.03%
Operating Cash Flow Q/Q Growth		 70.09% -141.05% 214.24% -187.09% -11.85% 53.20% -7.83% -111.10% 25.68% -9.36% -17.66%
Free Cash Flow Firm Q/Q Growth		 -7.82% -10.90% 1.71% 71.54% -200.71% 222.05% -189.70% -78.80% 66.93% 56.76% -189.80%
Invested Capital Q/Q Growth		 -127.97% 1,655.34% -112.93% -31.82% 112.59% 604.06% -192.46% 61.29% -178.28% -91.95% 22.69%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 46.96% -22,030.56% -23,264.22% -13,343.36% -89.01% -15,046.36% -22,713.90% -11,404.84% -14,390.97% -8,077.71%
Operating Margin		 0.00% 34.58% -27,894.25% -29,257.25% -18,294.02% -180.97% -17,158.84% -25,708.97% -14,854.78% -17,912.50% -8,933.33%
EBIT Margin		 0.00% 44.52% -22,989.48% -24,201.35% -14,130.56% -102.58% -15,593.87% -23,235.09% -11,903.49% -15,046.18% -8,373.94%
Profit (Net Income) Margin		 0.00% 44.41% -23,133.13% -24,450.29% -14,276.08% -104.54% -15,722.08% -23,379.93% -11,973.12% -15,117.25% -8,431.48%
Tax Burden Percent		 100.37% 99.74% 100.62% 101.03% 101.03% 101.91% 100.82% 100.62% 100.58% 100.47% 100.69%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 131.89% 0.00% -743,692.69% 0.00% -43.89% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 130.77% 0.00% -743,691.61% 0.00% -44.33% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -124.01% 0.00% 741,510.07% 0.00% 41.83% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.20% 7.88% -11.03% -2,182.62% -13.07% -2.06% -19.71% -25.34% -25.33% -30.18% -31.21%
Cash Return on Invested Capital (CROIC)		 0.00% -345.97% 0.00% 0.00% -6,197.88% -155.73% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 7.39% -2,667.51% -2,157.51% -1,319.88% -1.71% -255.15% -404.66% -202.75% -23.43% -14.05%
Return on Assets (ROA)		 0.00% 7.37% -2,684.17% -2,179.70% -1,333.47% -1.74% -257.25% -407.18% -203.94% -23.54% -14.14%
Return on Common Equity (ROCE)		 -19.20% 7.88% -11.03% -2,182.62% -13.07% -2.06% -19.71% -25.34% -25.33% -30.18% -31.21%
Return on Equity Simple (ROE_SIMPLE)		 -20.46% 0.00% -10.42% -13.42% -12.35% 0.00% -21.08% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -93 69 -98 -106 -77 -45 -104 -161 -92 -108 -91
NOPAT Margin		 0.00% 34.49% -19,525.97% -20,480.08% -12,805.81% -126.68% -12,011.19% -17,996.28% -10,398.35% -12,538.75% -6,253.33%
Net Nonoperating Expense Percent (NNEP)		 -1.05% 1.12% -0.91% -1.08% -0.48% 0.44% -1.62% -2.57% -0.72% -1.15% -1.71%
Return On Investment Capital (ROIC_SIMPLE)		 - 3.69% - - - -2.34% -5.68% -9.38% -4.82% -5.64% -3.80%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 8.19% 3,562.10% 3,768.09% 2,893.52% 50.78% 2,230.75% 2,120.63% 1,904.50% 2,129.51% 1,178.53%
R&D to Revenue		 0.00% 47.29% 15,113.49% 15,505.80% 13,647.84% 230.19% 8,379.65% 18,626.35% 6,625.65% 9,667.36% 4,703.29%
Operating Expenses to Revenue		 0.00% 65.42% 27,994.25% 29,357.25% 18,394.02% 280.97% 17,258.84% 25,808.97% 14,954.78% 18,012.50% 9,033.33%
Earnings before Interest and Taxes (EBIT)		 -112 90 -116 -125 -85 -37 -135 -207 -106 -130 -122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -107 94 -111 -120 -80 -32 -130 -203 -101 -124 -118
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.09 2.64 2.60 2.32 2.06 1.74 1.60 2.46 3.08 2.60 2.52
Price to Tangible Book Value (P/TBV)		 2.09 2.64 2.60 2.32 2.06 1.74 1.60 2.46 3.08 2.60 2.52
Price to Revenue (P/Rev)		 21.20 13.40 19.93 22.68 19.73 90.03 77.48 110.40 153.75 1,423.80 1,112.85
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 17.51 0.00 0.00 514.72 51.52 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.97 8.83 12.17 12.73 10.18 39.01 28.23 65.16 103.04 860.89 660.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32
Financial Leverage		 -1.01 -0.95 -1.01 -1.00 -1.00 -0.94 -1.01 -1.01 -1.01 -1.01 -1.02
Leverage Ratio		 1.21 1.19 1.19 1.19 1.18 1.17 1.18 1.18 1.17 1.17 1.34
Compound Leverage Factor		 1.21 1.19 1.19 1.19 1.18 1.17 1.18 1.18 1.17 1.17 1.34
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.39%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.39%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 75.61%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.07
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.07
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.29
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.10
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.29
Altman Z-Score		 6.15 9.24 9.45 7.80 7.71 6.60 5.01 7.38 10.44 8.31 2.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.83 17.54 17.81 15.73 21.64 22.07 15.64 16.61 16.22 13.32 17.96
Quick Ratio		 15.64 17.41 17.72 15.66 21.55 21.97 15.53 16.49 16.10 13.25 17.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -100 -111 -109 -31 -93 114 -102 -182 -60 -26 -76
Operating Cash Flow to CapEx		 -1,881.78% -13,018.02% 15,222.19% -13,519.38% -48,818.72% -19,697.24% -26,187.86% -97,333.33% -114,370.27% -17,901.93% -21,606.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.08 0.17 0.12 0.09 0.09 0.02 0.02 0.02 0.02 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.33 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.06 2.35 1.76 1.34 1.38 0.26 0.27 0.28 0.30 0.03 0.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 1,100.46 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 1,100.46 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 187 -24 -32 4.01 28 -26 -10 -28 -54 -42
Invested Capital Turnover		 -10.90 3.82 -9.24 36.31 -50.59 0.35 -1.50 -1.81 -3.18 -0.27 -0.12
Increase / (Decrease) in Invested Capital		 7.14 180 10 -75 16 -159 -1.94 22 -32 -82 -16
Enterprise Value (EV)		 1,865 3,277 3,306 2,574 2,066 1,456 1,064 2,479 3,950 3,022 2,710
Market Capitalization		 3,604 4,972 5,414 4,586 4,001 3,360 2,919 4,201 5,894 4,998 4,566
Book Value per Share		 $21.76 $23.70 $25.48 $23.33 $22.77 $22.64 $21.33 $19.81 $21.07 $20.17 $18.90
Tangible Book Value per Share		 $21.76 $23.70 $25.48 $23.33 $22.77 $22.64 $21.33 $19.81 $21.07 $20.17 $18.90
Total Capital		 1,728 1,883 2,084 1,981 1,940 1,932 1,829 1,711 1,916 1,922 2,400
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 585
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 585
Net Debt		 -1,740 -1,696 -2,108 -2,013 -1,936 -1,904 -1,855 -1,721 -1,944 -1,976 -1,856
Capital Expenditures (CapEx)		 2.12 0.74 0.72 0.71 0.22 0.25 0.21 0.12 0.07 0.52 0.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -90 106 -107 -119 -82 -54 -107 -92 -106 -139 -130
Debt-free Net Working Capital (DFNWC)		 1,649 1,799 2,001 1,883 1,854 1,849 1,748 1,629 1,810 1,837 2,312
Net Working Capital (NWC)		 1,649 1,799 2,001 1,883 1,854 1,849 1,748 1,629 1,810 1,837 2,312
Net Nonoperating Expense (NNE)		 19 -20 18 21 8.85 -7.90 32 48 14 22 32
Net Nonoperating Obligations (NNO)		 -1,740 -1,696 -2,108 -2,013 -1,936 -1,904 -1,855 -1,721 -1,944 -1,976 -1,856
Total Depreciation and Amortization (D&A)		 4.93 4.90 4.83 4.85 4.74 4.84 4.74 4.65 4.43 5.66 4.32
Debt-free, Cash-free Net Working Capital to Revenue		 -53.22% 28.45% -39.56% -58.86% -40.21% -145.99% -284.33% -241.61% -275.39% -3,968.01% -3,161.32%
Debt-free Net Working Capital to Revenue		 970.17% 484.71% 736.31% 930.93% 914.11% 4,956.18% 4,640.12% 4,282.01% 4,721.64% 52,323.39% 56,350.87%
Net Working Capital to Revenue		 970.17% 484.71% 736.31% 930.93% 914.11% 4,956.18% 4,640.12% 4,282.01% 4,721.64% 52,323.39% 56,350.87%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28)
Adjusted Weighted Average Basic Shares Outstanding		 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M
Adjusted Diluted Earnings per Share		 ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28)
Adjusted Weighted Average Diluted Shares Outstanding		 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 79.43M 80.28M 84.92M 85.17M 85.35M 85.77M 86.36M 90.95M 95.30M 95.99M 96.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -93 69 -98 -106 -77 -45 -104 -161 -92 -108 -91
Normalized NOPAT Margin		 0.00% 34.49% -19,525.97% -20,480.08% -12,805.81% -126.68% -12,011.19% -17,996.28% -10,398.35% -12,538.75% -6,253.33%
Pre Tax Income Margin		 0.00% 44.52% -22,989.48% -24,201.35% -14,130.56% -102.58% -15,593.87% -23,235.09% -11,903.49% -15,046.18% -8,373.94%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key four-year trends for CRISPR Therapeutics (CRSP) derived from quarterly statements. The bullets highlight items that may impact investors, ordered with positives first, then neutral points, then negatives.

  • CRSP secured a sizable financing boost in 2025: net cash from continuing financing activities was +$296.8 million in Q3 2025 and +$116.4 million in Q4 2025, improving liquidity and runway.
  • Investing activity supported cash flow in Q4 2025: sale/maturity of investments totaled about $300.7 million, contributing to net cash from investing activities of +$37.2 million.
  • Cash on hand remained robust in recent quarters: cash and cash equivalents were about $286.5 million at the end of Q3 2025, providing a liquidity buffer for ongoing R&D.
  • Revenue remains minimal (Q4 2025 operating revenue $0.864 million) and gross margin tracks revenue, consistent with an early-stage biotech profile.
  • Total assets grew from about $2.03B in Q2 2025 to about $2.25B in Q3 2025, signaling asset accumulation (cash, investments, etc.).
  • Total equity rose to about $1.92B by Q3 2025, driven by equity issuances, indicating dilution for existing shareholders but stronger liquidity.
  • Bottom-line losses persisted: net income attributable to common shareholders was -$127.6 million in Q4 2025, continuing a trend of substantial quarterly losses.
  • Operating cash flow remains negative: net cash from continuing operating activities was -$92.6 million in Q4 2025 (and was also negative in Q3 2025 and Q2 2025).
  • R&D spending remains very high and a primary driver of losses (Q4 2025 RD expense $83.5 million; Q2 2025 RD expense $166.1 million; Q3 2025 $58.9 million).
  • Significant cash outlays to investments (purchases of investments) have occurred in several quarters (e.g., Q3 2025 outflow of -$334.1 million; Q2 2025 outflow of -$215.1 million), underscoring cash allocated to portfolio holdings beyond operating needs.
05/25/26 01:34 PM ETAI Generated. May Contain Errors.

CRISPR Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CRISPR Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CRISPR Therapeutics' net income appears to be on an upward trend, with a most recent value of -$581.60 million in 2025, rising from -$25.83 million in 2015. The previous period was -$366.25 million in 2024. Find out what analysts predict for CRISPR Therapeutics in the coming months.

CRISPR Therapeutics' total operating income in 2025 was -$664.57 million, based on the following breakdown:
  • Total Gross Profit: $3.51 million
  • Total Operating Expenses: $668.08 million

Over the last 10 years, CRISPR Therapeutics' total revenue changed from $247 thousand in 2015 to $3.51 million in 2025, a change of 1,321.1%.

CRISPR Therapeutics' total liabilities were at $343.43 million at the end of 2025, a 10.8% increase from 2024, and a 176.9% increase since 2015.

In the past 10 years, CRISPR Therapeutics' cash and equivalents has ranged from $155.96 million in 2015 to $1.17 billion in 2020, and is currently $347.56 million as of their latest financial filing in 2025.

Over the last 10 years, CRISPR Therapeutics' book value per share changed from -5.78 in 2015 to 20.17 in 2025, a change of -449.1%.


Related Companies

Financial statements for NASDAQ:CRSP last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel